PTPRC and breast carcinoma: To test this within HER2-enriched and Basal-like breast cancers, we identify two extreme groups of tumors: one with high expression of CD45 (indicating intense immune infiltration) but low chronic inflammation markers and an opposite group with low expression of CD45 (indicating low immune infiltration) but high chronic inflammation markers.